Taking stock of the drug industry, from the lab to the medicine chestAugust 11, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Natsumi Chikayasu for STAT STAT+ | Inside the research machine that helps UnitedHealth protect its Medicare profits Experts say UnitedHealth's Medicare Advantage research may favor its business, citing possible conflicts of interest and restricted access to internal data. By Casey Ross, Bob Herman, Tara Bannow, and Lizzy Lawrence STAT+ | Dear Vinay: Please embrace dissent and fade into the background Prasad's boldness could serve as an asset at CBER if he can talk to his staff and understand the legal and regulatory hurdles he is facing. By Matthew Herper NIH director: mRNA vaccine contracts were canceled because public lacks trust in technology The explanation offered by Jay Bhattacharya does not not align with that of his boss, health secretary Robert F. Kennedy Jr. By Helen Branswell NIH STAT+ | Peptide vaccine could limit pancreatic cancer progression, small study finds A peptide vaccine showed strong immune responses in most pancreatic cancer patients in an early trial, hinting at a new way to stop recurrence. By Veronica Paulus STAT+ | Trump administration launches investigation into Harvard's federally funded research patents The Commerce Department begins the "march-in" process involving patent ownership and demands action from Harvard by Sept. 5. By Emily Spatz — Boston Globe More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments